Agency IQ

SEPTEMBER 6, 2023

The EPA’s Office of Pesticide Programs (OPP) Microbiology Laboratory Branch (MLB) has established standardized testing methods and procedures for pesticide products used to kill or suppress the growth of pathogenic microorganisms on inanimate objects and hard surfaces. EPA solicited comments from December 2022 through February 19, 2023.

Production 40

Production Virus Long-Term Care Facilities Laboratories 40

The Pharma Data

SEPTEMBER 18, 2020

has partnered with OmeCare, a CLIA-certified global clinical laboratory provider, to launch a new diagnostic test solution for Covid-19. Vivera Pharmaceutical provides Covid-19 results within 48 hours of initial patient test. Vivera Pharmaceuticals, Inc. ” Dr.

Vaccine 52

Vaccine Long-Term Care Facilities Clinical Supply Laboratories 52

The Pharma Data

JUNE 25, 2021

Participants were adults 18 years and over with potential exposure, within eight days, to a specific identified individual with laboratory-confirmed SARS-CoV-2 virus, symptomatic or asymptomatic, and who were therefore assessed at the time of enrolment to be at appreciable risk of imminently developing COVID-19.

Trials 52

Trials Virus Long-Term Care Facilities Government 52

The Pharma Data

NOVEMBER 9, 2020

Lilly’s chief scientific officer and president of Lilly Research Laboratories. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52

The Pharma Data

APRIL 16, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. “With the growing prevalence of variants in the U.S.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

MAY 4, 2021

Abnormal Laboratory Values: Evaluate at baseline and thereafter according to local patient management practice. Monitor closely when treating patients with abnormal baseline and post-baseline laboratory values. Manage patients according to routine clinical guidelines.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

JANUARY 26, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. have reached record highs.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52